TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total blood glucose exposure within 2 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean increase in peak oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neointimal volume obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Five-year patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Five-year freedom from acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Five-year actuarial freedom from allograft vasculopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean self-report scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alzheimer's Disease Assessment Scale, cognitive subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptom free patients after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for additional sessions after treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with protective anti-HBs titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titres of anti-HBs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Free from atrial arrhythmia recurrence >30 s off antiarrhythmic drugs
Endpoint domain: Mortality/survival
Primary endpoint: Arrhythmia-free survival on or off antiarrhythmic drugs
Endpoint domain: Mortality/survival
Primary endpoint: Total cost for transfused/administered blood products/coagulation factors per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days of infant hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of total body weight loss (%TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hrs plasma cortisol suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Heart rate increase above baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Expired CO concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective ratings elevation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fasting plasma GIP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting and postprandial leptin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of HE (Hemorrhagic Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of emergence coughing
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in night-time SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in daytime SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in osteoclast activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Decrease in bone mineral density in left ribs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Decrease in bone mineral density in lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Mineral loss of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to spontaneous recovery to TOF counts of 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in the 4-week frequency of satisfying sexual episodes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Thinnest corneal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior surface HOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of seclusion and restraint
Endpoint domain: Adverse events/effects
Primary endpoint: Circulating testosterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum plasma concentrations of lidocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Whole-body exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced resident agitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NP recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: synechia formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transient increases in liver enzymes
Endpoint domain: Adverse events/effects
Primary endpoint: Nausea, vomiting, headache, and fatigue
Endpoint domain: Adverse events/effects
Primary endpoint: positive skin culture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: diarrhoea duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: ORS consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in epidermal pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: KCCQ overall summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median time to first start following diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction in VAS scores for burning and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in vibratory perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of grade 2 hypoglycaemic events per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment satisfaction with CIPII
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rates of nocturnal confirmed hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to asystole after aortic cross‐clamping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean cardiac index immediately post CPB and 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Requirement for inotropic support after CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in blood flow to the left side of the sternum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to full feedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in sensory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in sudomotor, vasomotor, and pilomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in nerve fiber densities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 10-year biochemical failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative weight loss in the 1st 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consolidation treatment effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 25% T1 twitch recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to train-of-four ratio of 0.7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in maladaptive interpersonal behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: muscle inactivity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: light muscle activity time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average EMG amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4+ T cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean number of wet nights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of a wet episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone height gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status at discharge from the ICU
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Lens preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Live donor kidney transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Duration of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of oral ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed chair rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean verbal training time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time for actuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rating of system ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insulin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HbA(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Uncorrected Visual Acuity (UCVA) of 20/32 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) of 20/25 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean refractive cylinder reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MLD poststenting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: in-stent obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Severity of pain (VAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fentanyl consumed postoperatively
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ischemic heart disease defects on scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tear osmolarity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CM syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission (glycosylated hemoglobin < 6.5% and normal oral glucose tolerance test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: β-cell glucose sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Photosensitivity resolution time
Endpoint domain: Adverse events/effects
Primary endpoint: Uterine artery PI changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Menstrual pain intensity changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total 24-h morphine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic donor site pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total postoperative analgesic consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first request for rescue analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with excellent pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Probability of being seizure-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Median total seizure frequency per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Safety and tolerability of levetiracetam
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in AAA diameter measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute pancreatitis events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum lipase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum amylase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: whole-body protein balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean glucose iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum-insulin iAUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Delay to initial defibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of communication statements
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: cholesterol efflux to HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anti-HBsAg titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain and distension ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose concentration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CDRS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of being a responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall response rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Affective pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor block incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of instrumental delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stable serum digoxin levels within non-toxic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulation to toxic levels
Endpoint domain: Adverse events/effects
Primary endpoint: Therapeutical serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: better clinical outcomes following ABM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival free from regional and distant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients who required no opioid during treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean mfERG latency reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean mfERG response density improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic outcome in eczema response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arteriovenous passage time of fluorescein dye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: narrative insight
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: CSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDD (Flow-mediated dilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: UA (Uric Acid)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bayley psychomotor mean scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of high-risk maternal-child interactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: High-risk home environment prevalence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: muscle mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total economic cost of the Promise-EBF intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Recovery rates in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of drowsiness
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in central subfield retinal thickness (CSRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients gaining 0-≥15 letters in Early Treatment Diabetic Retinopathy Study letters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertension and tachycardia during anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Delirium, nausea, and vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunisation errors
Endpoint domain: Adverse events/effects
Primary endpoint: Healthcare professional satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: rate of tumor recurrence
Endpoint domain: Mortality/survival
Primary endpoint: rate of tumor progression
Endpoint domain: Mortality/survival
Primary endpoint: Daily food glucose load (GL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 2 h postprandial glucose (2 h PG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean BUP‐Gluc:NBUP‐Gluc ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent daily dose excreted during pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: D90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conformal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Sensitivity (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rectal blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mucus parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of SUVN-502
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile (AUC and Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in per cent atheroma volume (PAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mortality of intensive insulin‐treated patients
Endpoint domain: Mortality/survival
Primary endpoint: Psoriatic Arthritis Response Criteria response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI 50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Pulse Pressure (cPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Liver enzymes in NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in bladder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urinary urge incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in voiding frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved bleeding scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes